ENTA.US Enanta Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
10.99 USD
Close of Nov 14, 2026
10.05 17.15
Market cap
USD 320M
P/E
-
P/B
3.22x
ROE
-58.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.

Is ENTA.US undervalued?

Graham number

The Graham number of Enanta Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Enanta Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Enanta Pharmaceuticals Inc yet.

Enanta Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the t…

Full company profile